Limited Recovery of β-Cell Function After Gastric Bypass Despite Clinical Diabetes Remission
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
The mechanisms responsible for the remarkable remission of type 2 diabetes after Roux-en-Y gastric bypass (RYGBP) are still puzzling. To elucidate the role of the gut, we compared β-cell function assessed during an oral glucose tolerance test (OGTT) and an isoglycemic intravenous glucose clamp (iso-IVGC) in: 1) 16 severely obese patients with type 2 diabetes, up to 3 years post-RYGBP; 2) 11 severely obese normal glucose-tolerant control subjects; and 3) 7 lean control subjects. Diabetes remission was observed after RYGBP. β-Cell function during the OGTT, significantly blunted prior to RYGBP, normalized to levels of both control groups after RYGBP. In contrast, during the iso-IVGC, β-cell function improved minimally and remained significantly impaired compared with lean control subjects up to 3 years post-RYGBP. Presurgery, β-cell function, weight loss, and glucagon-like peptide 1 response were all predictors of postsurgery β-cell function, although weight loss appeared to be the strongest predictor. These data show that β-cell dysfunction persists after RYGBP, even in patients in clinical diabetes remission. This impairment can be rescued by oral glucose stimulation, suggesting that RYGBP leads to an important gastrointestinal effect, critical for improved β-cell function after surgery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis
Buchwald, H., Estok, R., Fahrbach, K., Banel, D., Jensen, M. D., Pories, W. J., Bantle, J. P., & Sledge, I. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.041 · Cited by 2,551 · cited 1×
“Roux-en-Y gastric bypass (RYGBP) remits type 2 diabetes in ;40–80% of cases (1,2); however, mechanisms surrounding this remarkable improvement are still elusive.”
BackgroundBariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes
Schauer, P. R., Kashyap, S. R., Wolski, K., Brethauer, S. A., Kirwan, J. P., Pothier, C. E., Thomas, S., Abood, B., Nissen, S. E., & Bhatt, D. L. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200225 · Cited by 2,164 · cited 1×
“Roux-en-Y gastric bypass (RYGBP) remits type 2 diabetes in approximately 40-80% of cases (1; 2), however mechanisms surrounding this remarkable improvement are still elusive.”
BackgroundLaferrère, B., Teixeira, J., McGinty, J., Tran, H., Egger, J. R., Colarusso, A., Kovack, B., Bawa, B., Koshy, N., Lee, H., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2851 · Cited by 682 · cited 1×
“OB-DM subjects underwent laparoscopic RYGBP with a 30-mL gastric pouch, 40-cm afferent limb, 150-cm Roux limb, and 12-mm gastrojejunostomy, as described previously (19).”
MethodThe Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
Utzschneider, K. M., Prigeon, R. L., Faulenbach, M. V., Tong, J., Carr, D. B., Boyko, E. J., Leonetti, D. L., McNeely, M. J., Fujimoto, W. Y., & Kahn, S. E. (2009) · Diabetes Care · doi:10.2337/dc08-1478 · Cited by 572
Laferrère, B., Heshka, S., Wang, K., Khan, Y., McGinty, J., Teixeira, J., Hart, A. B., & Olivan, B. (2007) · Diabetes Care · doi:10.2337/dc06-1549 · Cited by 532
Self-citationArterburn, D. E., Bogart, A., Sherwood, N. E., Sidney, S., Coleman, K. J., Haneuse, S., O’Connor, P. J., Theis, M. K., Campos, G. M., McCulloch, D., et al. (2013) · Obesity Surgery · doi:10.1007/s11695-012-0802-1 · Cited by 426 · cited 1×
“Using more stringent criteria (32,33), we observed some deterioration of glucose control at 3 years, which is consistent with recent data showing diabetes remission wanes from 1 to 3 years (34).”
ResultMuscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J. J., & Ferrannini, E. (2008) · Diabetes · doi:10.2337/db07-1315 · Cited by 409 · cited 3×
“BCGS, impaired in diabetes, shown in this study and in others (12,13), increases acutely (1–6 weeks) after RYGBP, with little further improvement longer term (3–12 months) (13–15).”
Background
Cited by
Mechanisms of diabetes improvement following bariatric/metabolic surgery
Batterham, R. L., & Cummings, D. E. (2016) · Diabetes Care · doi:10.2337/dc16-0145 · Cited by 376
“matched obese nonsurgical control subjects (46,47), whereas others contest this assertion (37,38).”
BackgroundMethodResultInfluentialβ-cell dysfunction: Its critical role in prevention and management of type 2 diabetes
Saisho, Y. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i1.109 · Cited by 263
Narath, S. H., Mautner, S. I., Svehlikova, E., Schultes, B., Pieber, T. R., Sinner, F. M., Gander, E., Libiseller, G., Schimek, M. G., Sourij, H., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0161425 · Cited by 65
“Such rapid metabolic changes and very individual responses to gastric bypass surgery are not yet fully understood [17].”
Background
Metadata
- Authors
- Dutia, R., Brakoniecki, K., Bunker, P., Paultre, F., Homel, P., Carpentier, A. C., McGinty, J., & Laferrère, B.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-03-13
- Volume
- 63
- Issue
- 4
- Pages
- 1214-1223
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2137892791
- Cited by
- 84
- References
- 15
- FWCI
- 11.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.